ArticleBlood cancer journal2018
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Risk factors for leukemic transformation in myeloproliferative neoplasms and prognostic factors in secondary acute myeloid leukemia: an exploratory analysis of the SEER database.Annals of hematology · 2026Article
- Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis.HemaSphere · 2026Article
- Gender influences prognosis of classical BCR::ABL1 negative myeloproliferative neoplasms: a retrospective cohort study.Discover oncology · 2025Article
- Topics of Interest in Women With Myeloproliferative Neoplasms.American journal of hematology · 2025Review
- Management of Bleeding, Thrombotic and Pregnancy-Related Complications in Women with Myeloproliferative Neoplasms: A Case-Based Review Focusing on Sex-Specific Challenges.Journal of clinical medicine · 2025Review
- Association between JAK2Irish journal of medical science · 2024Article
- Myeloproliferative Neoplasms: Challenging Dogma.Journal of clinical medicine · 2024Review
- Prognostic and Predictive Models in Myelofibrosis.Current hematologic malignancy reports · 2024Review
- Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database.Annals of hematology · 2024Article
- Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients.Scientific reports · 2024Article
- Article
- Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.Leukemia · 2022Article
- Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.Current hematologic malignancy reports · 2022Review
- Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.British journal of haematology · 2021Article
- Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology.International journal of molecular sciences · 2021Review
- Distinct profile of CD34Journal of experimental & clinical cancer research : CR · 2021Article
- Is there a gender effect in polycythemia vera?Annals of hematology · 2021Review
- Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden.Blood advances · 2020Article
- Disease-Specific Derangement of Circulating Endocannabinoids andInternational journal of molecular sciences · 2020Article
- Standard care and investigational drugs in the treatment of myelofibrosis.Drugs in context · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Daniela BarracoHematology, Department of Medicine and Surgery, University of Insubria & Ospedale di Circolo, ASST Sette Laghi, Varese, Italy.
Barbara MoraHematology, Department of Medicine and Surgery, University of Insubria & Ospedale di Circolo, ASST Sette Laghi, Varese, Italy.
Paola GuglielmelliCRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Department of Experimental and Clinical Medicine, Azienda ospedaliera-Universitaria Careggi, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0003-1809-284X
Elisa RumiDepartment of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Pavia, Italy.
Margherita MaffioliHematology, Department of Medicine and Surgery, University of Insubria & Ospedale di Circolo, ASST Sette Laghi, Varese, Italy.
Alessandro RambaldiDepartment of Oncology-Hematology, University of Milan and BMT Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.ORCID http://orcid.org/0000-0002-3739-7502
Marianna CaramellaOspedale Niguarda Cà Granda, Milano, Italy.
Rami KomrokjiMoffit Cancer Center, Tampa, FL, USA.
Jason GotlibStanford University, Palo Alto, CA, USA.
Jean Jacques KiladjianHôpital Saint-Louis et Université Paris Diderot, Paris, France.
Francisco CervantesHospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Timothy DevosDepartment of Hematology, University Hospitals Leuven and Laboratory of Experimental Transplantation, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
Francesca PalandriPoliclinico S. Orsola-Malpighi, Bologna, Italy.
Valerio De StefanoUniversità Cattolica del Sacro Cuore, Roma, Italy.ORCID http://orcid.org/0000-0002-5178-5827
Marco RuggeriOspedale S. Bortolo, Vicenza, Italy.
Richard T SilverWeill Cornell Medical College, New York, NY, USA.
Giulia BenevoloSC Hematology, A.O. Città della Salute e della Scienza, Turin, Italy.
Francesco AlbanoUniversità di Bari, Bari, Italy.
Michele MerliHematology, Department of Medicine and Surgery, University of Insubria & Ospedale di Circolo, ASST Sette Laghi, Varese, Italy.
Daniela PietraDepartment of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Pavia, Italy.
Tiziano BarbuiResearch Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy.
Giada RotunnoCRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Department of Experimental and Clinical Medicine, Azienda ospedaliera-Universitaria Careggi, University of Florence, Florence, Italy.
Mario CazzolaDepartment of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Pavia, Italy.
Toni GiorginoBiophysics Institute, National Research Council of Italy, c/o Department of Biosciences, University of Milan, via Celoria 26, I-20133, Milan, Italy.ORCID http://orcid.org/0000-0001-6449-0596
Alessandro Maria VannucchiCRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, Department of Experimental and Clinical Medicine, Azienda ospedaliera-Universitaria Careggi, University of Florence, Florence, Italy.
Francesco PassamontiHematology, Department of Medicine and Surgery, University of Insubria & Ospedale di Circolo, ASST Sette Laghi, Varese, Italy. francesco.passamonti@uninsubria.it.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
GenotypePhenotypeAdultAgedAged, 80 and overBiomarkersFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansMaleMiddle AgedPolycythemia VeraPrimary MyelofibrosisPrognosisSeverity of Illness IndexBiomarkers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.